CAR-T Cell Therapy for Multiple Myeloma Market Size, Share and Growth Analysis 2025 to 2034
What is CAR-T Cell Therapy for Multiple Myeloma Market Size?
Global CAR-T Cell Therapy for Multiple Myeloma Market Size is valued at USD 2.32 Billion in 2025 and is predicted to reach USD 9.28 Billion by the year 2035 at an 15.0% CAGR during the forecast period for 2026 to 2035.
CAR-T Cell Therapy for Multiple Myeloma Market Size, Share & Trends Analysis Report By Therapy Type (Bb2121, JNJ-68284528 (LCAR-B38M), P-BCMA-101, CAR-CD44V6, Others), By Region, And Segment Forecasts, 2026 to 2035.

CAR-T Cell Therapy for Multiple Myeloma Market Key Takeaways:
|
Chimeric Antigen Receptor (CAR) T cell therapy is an innovative treatment that encompasses the reengineering of white blood cells (WBC) of a cancer patient’s to fight the malignant cells by identifying them. CAR-T cell therapy is approved for certain types of blood cancer. The blood cancer type, multiple myeloma affects plasma cells. In multiple myeloma, the malignant cells accrue in the bone marrow (the spongy, soft tissue at the middle of bones), gathering out the normal plasma cells that help fight contamination. These malicious plasma cells then produce M protein, an atypical antibody that offers no advantage to the body and might cause kidney damage, tumors, bone obliteration, and reduced immune function. The high level of M protein in blood denotes the characteristics of multiple myeloma.
The Multiple Myeloma is infrequently curable, but it is an extremely manageable disease that has seen speedy medical development over the past few years. The development of the Multiple Myeloma Research Foundation (MMRF) has improved the research activities to develop the most promising treatments for multiple myeloma. CAR T-cell therapy for multiple myeloma is one advanced immunotherapy to program the immune system to attack cancer. The CAR-T Cell therapy for multiple myeloma market size is expected to reach US$ xx million by 2030, growing at a CAGR of xx% over the forecast period. The rising prevalence of multiple myeloma is anticipated to foster the growth CAR T-cell therapy for multiple myeloma market globally. The presence of potential pipeline drugs to treat multiple myeloma is expected to boost the growth of the market in the coming years. However, high costs associated with CAR T-cell therapy owing to the high cost of research and development activities may hamper the growth of the market substantially over the estimated time frame.
Competitive Landscape
Some Of The key players in the CAR-T Cell Therapy for Multiple Myeloma Market:
- Bluebird bio/Celgene,
- Poseida Therapeutics,
- MolMed S.p.A.,
- Janssen Research & Development,
- Celgene Corporation,
- CARsgen Therapeutics,
- Cartesian Therapeutics,
- Precision BioSciences.
Market Segmentation
Global CAR-T cell therapy for multiple myeloma market is segmented based on therapy type, and country. Based on the therapy type, the CAR T-cell therapy for multiple myeloma market is segmented into JNJ-68284528 (LCAR-B38M), Bb2121, CAR-CD44V6, P-BCMA-101, and others. Currently, there is no approved CAR- T cell therapy for multiple myeloma in the market. The presence of strong candidates under development stages is expected to accelerate the growth of the market in the coming years. Additionally, various research firms are trying combination therapy to treat multiple myeloma. The recent development in the understanding of immunology has permitted companies to develop new immunotherapeutic methods, that are effective in various cancers, including multiple myeloma. Based on the country, the market is studied across The US, Germany, France, the UK, Italy, and the Rest of the World.
CAR-T Cell Therapy for Multiple Myeloma Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 2.32 Billion |
| Revenue Forecast In 2035 | USD 9.28 Billion |
| Growth Rate CAGR | CAGR of 15.0% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Therapy Type |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Bluebird bio/Celgene, Poseida Therapeutics, MolMed S.p.A., Janssen Research & Development, Celgene Corporation, CARsgen Therapeutics, Cartesian Therapeutics, and Precision BioSciences. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
CAR-T Cell Therapy for Multiple Myeloma Market Segmentation:
CAR-T Cell Therapy for Multiple Myeloma Market, by Therapy Type :
- Bb2121
- JNJ-68284528 (LCAR-B38M)
- P-BCMA-101
- CAR-CD44V6
- Others

CAR-T Cell Therapy for Multiple Myeloma Market, Based on Region:
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
CAR-T Cell Therapy for Multiple Myeloma Market is expected to grow at a 15.0% CAGR during the forecast period for 2026 to 2035
Bluebird bio/Celgene, Poseida Therapeutics, MolMed S.p.A., Janssen Research & Development, Celgene Corporation, CARsgen Therapeutics, Cartesian Therapeutics, , Precision BioSciences and Others.
Therapy Type is the key segment of the CAR-T Cell Therapy for Multiple Myeloma Market.
North American region is is expected to lead the CAR-T Cell Therapy for Multiple Myeloma Market.
CAR-T Cell Therapy for Multiple Myeloma Market Size is valued at USD 2.32 Billion in 2025 and is predicted to reach USD 9.28 Billion by the year 2035
